Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

L-dopa in hepatic coma.

J E Fischer, F J Funovics, H A Falcao

    Annals of Surgery
    |April 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Early L-Dopa treatment for hepatic coma shows promise. Initiating therapy within 1.4 days of coma onset significantly improved survival rates in patients with severe liver disease.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Endotoxemia and IL-1 beta stimulate mucosal IL-6 production in different parts of the gastrointestinal tract.

    The Journal of surgical research·1998
    Same author

    Proteasome blockers inhibit protein breakdown in skeletal muscle after burn injury in rats.

    Clinical science (London, England : 1979)·1998
    Same author

    Effect of collection and preprocessing methods on neutrophil elastase plasma concentrations.

    Clinical biochemistry·1998
    Same author

    The anabolic effects of IGF-1 in skeletal muscle after burn injury are not caused by increased cell volume.

    JPEN. Journal of parenteral and enteral nutrition·1998
    Same author

    Percutaneous central venous catheterization in premature infants: a method for facilitating insertion of silastic catheters via peripheral veins.

    Pediatrics·1998
    Same author

    IGF-I stimulates protein synthesis but does not inhibit protein breakdown in muscle from septic rats.

    The American journal of physiology·1998
    Same journal

    Real-world Safety and Performance of the Symani Surgical System® in Microsurgical Reconstructive Procedures: Primary Results from the PRIMO Study.

    Annals of surgery·2026
    Same journal

    Revisiting Simultaneous Liver and Kidney Transplantation from Donors After Circulatory Death in the Era of Machine Perfusion Technologies: A US Nationwide Analysis of 10,687 Cases.

    Annals of surgery·2026
    Same journal

    The International Medical Graduate Paradox.

    Annals of surgery·2026
    Same journal

    Defining the Incremental Value of Endoscopic Ultrasound in Assessing Pancreatic Cystic Neoplasms.

    Annals of surgery·2026
    Same journal

    Trends in Metabolic and Bariatric Surgery and GLP-1 Receptor Agonist Use Among Adolescents with Severe Obesity.

    Annals of surgery·2026
    Same journal

    The Ambulatory Surgery Center Paradox: Why 60% of Surgeries Occur Where 2% of AI Research Happens.

    Annals of surgery·2026
    See all related articles

    Area of Science:

    • Hepatology
    • Neurology
    • Pharmacology

    Background:

    • Hepatic coma is a severe complication of liver disease.
    • L-Dopa has been explored as a treatment for hepatic coma since 1970.
    • Previous treatments include protein restriction and antibiotics.

    Purpose of the Study:

    • To evaluate the efficacy of L-Dopa in treating hepatic coma.
    • To determine the optimal timing for L-Dopa initiation in hepatic coma patients.

    Main Methods:

    • A heterogeneous group of 35 patients with severe liver disease and hepatic coma (grades III and IV) were treated.
    • L-Dopa was administered orally or via retention enema.
    • Patients received standard supportive care including protein restriction and antibiotics.

    Related Experiment Videos

    Main Results:

    • Five patients (14%) responded to L-Dopa and survived.
    • Seventeen patients (49%) responded but did not survive.
    • Thirteen patients (37%) did not respond to therapy.
    • Early initiation of L-Dopa (within 1.4 days of coma onset) was associated with significantly better outcomes compared to later initiation (6.7-9.5 days).

    Conclusions:

    • L-Dopa therapy may offer benefits in managing hepatic coma.
    • The timing of L-Dopa administration is critical, suggesting a reversible to irreversible stage transition in coma.
    • Early intervention with L-Dopa is recommended for potentially improving survival in hepatic coma.